Results 71 to 80 of about 9,287,329 (300)
Noninvasive Evaluation of Portal Hypertension: Emerging Tools and Techniques
Portal hypertension is the main cause of complications in patients with cirrhosis. However, evaluating the development and progression of portal hypertension represents a challenge for clinicians.
V. K. Snowdon +2 more
doaj +1 more source
Abstract Cyclizine is a long‐established, short‐acting drug, registered for preventing motion sickness, post‐operative nausea and vomiting (PONV) and ‘vomiting of known cause’. The latter is not defined but may include pregnancy and patients receiving palliative care, historically accepted without large, controlled trials.
Gareth J. Sanger, Paul L. R. Andrews
wiley +1 more source
Resolution of Severe Portopulmonary Hypertension With Inhaled Treprostinil and Liver Transplantation [PDF]
Portopulmonary hypertension is a rare condition with a poor prognosis. Prompt management is essential for liver transplantation eligibility, a potentially curative option.
Alex J. Chang, MD, Choon Hwa Goh, MD
doaj +1 more source
Novel therapeutics for portal hypertension and fibrosis in chronic liver disease. [PDF]
Portal hypertension (PH) is the most common non-neoplastic complication of chronic liver disease, determining clinical complications that lead to death or liver transplantation.
Xie, Wei-Fen +7 more
core +1 more source
ABSTRACT Inconsistencies exist in anatomy and clinical reference texts regarding the vertebral levels of major abdominal structures. Accurate surface anatomy is essential for diagnostic interpretation and interventional procedures, yet little is known about how health status or pathology may influence the vertebral relationships of abdominal organs ...
Masroor Badshah +3 more
wiley +1 more source
CYP2D6‐Guided Opioid Therapy for Chronic Pain: A Multi‐Center Pragmatic Randomized Controlled Trial
The analgesic effectiveness of several opioids depends on CYP2D6‐mediated metabolism to more active opioid receptor agonists. CYP2D6 activity is impacted by genetic variability and medications that inhibit CYP2D6. We conducted a pragmatic, multi‐center, randomized, controlled trial to determine whether CYP2D6‐guided opioid prescribing improves chronic ...
Todd C. Skaar +255 more
wiley +1 more source
The future treatment of portal hypertension
Increased understanding of the hyperdynamic circulation syndrome has resulted in novel therapeutic approaches, some of which have already reached clinical practice.
Lebrec, Didier, Reichen, Jürg
core +1 more source
Abstract Early diagnosis of hepatocellular carcinoma (HCC) remains challenging because conventional serum biomarkers, especially alpha‐fetoprotein (AFP), show limited sensitivity for early‐stage disease. Recent progress in engineered molecular diagnostics provides new opportunities to improve HCC detection through integrated material, molecular, and ...
Jingzhi Xue +5 more
wiley +1 more source
Portal hypertension is a common syndrome with serious clinical consequences. Some aspects of pathophysiology, causes and clinical features are discussed.
Martinelli, Ana L. Candolo
core +1 more source
Pathophysiology of Portal Hypertension [PDF]
Portal hypertension is a major complication of liver disease that results from a variety of pathologic conditions that increase the resistance to the portal blood flow into the liver. As portal hypertension develops, the formation of collateral vessels and arterial vasodilation progresses, which results in increased blood flow to the portal circulation.
openaire +2 more sources

